Business
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform
BOSTON, April 07, 2026--Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced a collaboration and license agreement with Biogen Inc. for the use of Alloy’s novel and proprietary AntiClastic™ ASO Platform. Through this collaboration, Biogen will apply the platform to advance antisense therapeutics against multiple undisclosed targets. Alloy will receive an upfront payment and is eligible
About this update from Biogen Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":8001,"height":2684,"url":"https://media.zenfs.com/en/business-wire.com/a25e631063eebd4fc5acf9c4cf25cfeb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/62j29oXY8g3E9i2beAQ.4Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMg--/https://media.zenfs.com/en/business-wire.com/a25e631063eebd4fc5acf9c4cf25cfeb","width":960,"height":322},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Olrcq7nwVzaGvSI9w6FsbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDY-/https://media.zenfs.com/en/business-wire.com/a25e631063eebd4fc5acf9c4cf25cfeb","width":1200,"height":403}},"lazy":false},{"type":"text","content":"- Collaboration leverages Alloy’s platform to accelerate the development of innovative oligonucleotide therapeutics- Latest collaboration between the two companies builds on past work together, including Biogen's use of Alloy's AI-enabled transgenic mouse platform","length":273,"tagName":"p"},{"type":"text","content":"BOSTON, April 07, 2026--(BUSINESS WIRE)--Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced a collaboration and license agreement with Biogen Inc. for the use of Alloy’s novel and proprietary AntiClastic™ ASO Platform. Through this collaboration, Biogen will apply the platform to advance antisense therapeutics against multiple undisclosed targets. Alloy will receive an upfront payment and is eligible for additional milestone payments and tiered royalties on any products resulting from the collaboration.","length":631,"tagName":"p"},{"type":"text","content":"The collaboration and license agreement brings together Biogen’s scientific leadership and experience in advancing innovative medicines with Alloy’s proprietary antisense discovery capabilities. Alloy’s AntiClastic ASO platform enables drug developers to realize the full potential of antisense therapeutics by reaching intracellular disease targets at the RNA level. The platform is specifically designed to address potency and therapeutic index challenges that have historically held back the promise of antisense drugs due to limited biodistribution, and therefore, efficacy.","length":578,"tagName":"p"},{"type":"text","conten...